Precision Biosciences (DTIL) Cash & Equivalents (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Cash & Equivalents data on file, last reported at $99.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $99.4 million, up 28.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.4 million (up 28.68% YoY), and the FY2025 annual result was $110.8 million, up 29.02% from the prior year.
• Cash & Equivalents fell to $99.4 million in Q1 2026 per DTIL's latest filing, from $110.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $212.1 million in Q3 2022 and troughed at $44.9 million in Q3 2025.
• A 5-year average of $122.2 million and a median of $116.7 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents jumped 36.06% in 2023, then plunged 54.56% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $189.6 million in 2022, then tumbled by 38.45% to $116.7 million in 2023, then decreased by 26.38% to $85.9 million in 2024, then gained by 29.02% to $110.8 million in 2025, then fell by 10.33% to $99.4 million in 2026.
• Business Quant data shows DTIL's Cash & Equivalents at $99.4 million in Q1 2026, $110.8 million in Q4 2025, and $44.9 million in Q3 2025.